Journal Article Cites HemoVoid™ in Proteomic Study of Gaucher Disease

MONMOUTH JUNCTION, N.J. - Sept. 30, 2021 - PRLog -- Biotech Support Group reports on a research article describing the simplicity and efficiency of their hemoglobin depletion technology for enriching blood proteins, in order to profile the proteome of Gaucher disease relative to normal controls.

The citation is:

Pawliński, Łukasz, et al. "Proteomic biomarkers in Gaucher disease (https://jcp.bmj.com/content/74/1/25.long)." Journal of clinical pathology 74.1 (2021): 25-29.

The research work was conducted to find new biomarkers and potential drug targets in Gaucher disease type 1 (GDt1) by analyzing serum proteins. For proteomics, quantitative analysis was performed by the isobaric tag for a relative and absolute quantitation (iTRAQ) method (Sciex, Framingham, Massachusetts). The article states "Cells were lysed in lysis buffer (7 mol/L urea, 2 mol/L thiourea, 4% CHAPS, 1% DTT …, vortexed, incubated at 25°C for 30 min and then centrifuged at 12 000×g for 15 min…the samples were purified using HemoVoid resin (Biotech Support Group) to remove haemoglobin contamination. The study found 31 proteins that significantly differed in concentration between GDt1 patients and a control group. These were mostly proteins involved in the regulation of inflammatory processes and haemostasis.

"Through more efficient methods to measure the blood proteome – red cells, white cells, platelets and plasma, our products now contribute to understanding how these compartments cross-communicate. Those connections all play a role in normal homeostasis and in disease. This article illustrates how the blood proteome can be analyzed by LC-MS, in order to discover potential new biomarkers and a better understanding of Gaucher disease.", states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for Covid-19 and cancer patients. For more information, go to http://www.biotechsupportgroup.com

For Business Development, Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com (mailto:sales@biotechsupportgroup.com)